Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Oncolytics Biotech Inc.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== '''Management Team at Oncolytics Biotech.:''' === '''Matt Coffey, PhD, MBA''' is the '''Chief Executive Officer and President''' of Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncolytics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer. [[File:Screenshot 2023-07-22 at 11.00.53.png|thumb|188x188px|Kirk Look - CFO ]] '''Kirk Look''' is the '''Chief Financial Officer''' of Oncolytics and is a highly experienced chartered accountant. Before joining the company in 2003 Look was the manager of Audit and Assurance services in the prestigious accounting firm Ernst & Young in Canada. [[File:Screenshot 2023-07-22 at 11.07.29.png|thumb|179x179px|Allison Hagerman - Vice President ]] '''Allison Hagerman''' is the '''Vice President of Product Development''' at Oncolytics. Ms. Hagerman is a biotechnology professional engineer and has been Director of Manufacturing and Engineering and Project Manager in Oncolytics. During this time she led the team to for the performance qualification of Pelareorep drug substance. [[File:Screenshot 2023-07-22 at 11.07.38.png|thumb|171x171px|Andrew de Guttadauro - Global head of Business Development, President ]] '''Andrew de Guttadauro''' is the '''President and Global Head of Business Development''' at Oncolytics Biotech. Mr. Guttadauro has held executive and senior-level positions at leading pharmaceutical and biotechnology companies. '''Thomas C. Heineman, MD, PhD''' is the '''Chief Medical Officer''' of Oncolytics. He completed his PhD at the University of Chigaco in Virology.Β Prior to his position in Oncolytics Dr Heineman worked in various roles which were Head of clinical development at Denovo, Vice President, Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics, Senior Director of Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)